Emory Joins DARPA-Funded Ebola Research and Development Team Led by Inovio Pharmaceuticals
Dr. Rafi Ahmed, faculty member in IMP and MMG, discusses Emory's research in conducting clinical trials and analyzing immune responses induced by the Ebola vaccine. Emory is part of a government-academic-industry research partnership led by Inovio Pharmaceuticals, Inc. to develop multiple treatment and prevention approaches against Ebola. The Inovio research team is funded by a two-year contract of up to $45 million from the Defense Advanced Research Projects Agency (DARPA).
Inovio’s Ebola program is initially targeted to treat first responders and Ebola-infected health care workers and patients, but could potentially be widely used to stem the spread of the current or subsequent outbreaks.
Click here to read the full article in the Emory News Center